The FDA cleared AtCor Medical’s SphygmoCor XCEL systems, a new blood pressure cuff-based device which could streamline central aortic blood pressure and arterial stiffness measurement.
SphygmoCor XCEL systems could enable traditional brachial blood pressure measurement, pulse wave analysis and velocity measurement to be performed quickly and easily, according to a press release.
"The reaction from physicians and from our pharmaceutical clinical trials customers has been extremely positive," CEO Duncan Ross said in prepared remarks. "SphygmoCor XCEL offers users the gold standard in pulse wave analysis and pulse wave velocity measurement, featured in over 600 published studies, in a cuff-based system that is very easy to use."
The device sequentially measures brachial blood pressure and central aortic pressure, providing comprehensive cardiovascular data for diagnosis, risk assessment and drug therapy management, Ross added.
SphygmoCor XCEL is currently available for sale in European, Australia, and in some Asian markets. The company earlier this month introduced the product at the American Society of Nephrology conference in San Diego.
